quantic69/iStock via Getty Images
- Vertex Pharmaceuticals (NASDAQ:VRTX) said that new data on Casgevy (exagamglogene autotemcel) demonstrates the benefits of the gene therapy for severe sickle cell disease or transfusion-dependent beta thalassemia over the long term.
- For sickle cell disease, 95.6% of evaluable patients (those with at least